Displaying 1–10 of 15 for “reneuron”
Feb 21, 2019
ReNeuron, a cellular therapy developer in the UK, has reported vision improvements in the treated eyes of the first three retinitis pigmentosa (RP) patients in the Phase II part of the Phase I/II clinical trial for its proprietary human retinal progenitor cells (hRPC). The Phase I portion of the trial, completed last year, primarily assessed safety in subjects with minimal remaining vision.
Apr 29, 2019
The latest ReNeuron results were presented at the sixth annual Retinal Cell and Gene Therapy Innovation Summit held on April 26 in Vancouver, Canada.
Oct 18, 2019
The Foundation funded earlier lab studies that made the clinical trial possible.
Jan 19, 2022
Company seeks to out-license its retinal progenitor therapy to a partner
Nov 15, 2019
Phase 1/2a human study will evaluate neural progenitors for preserving vision
Mar 20, 2014
Dr. Henry Klassen’s progenitor-based therapy has the potential to rescue a variety of retinal cells — including rods, cones, retinal pigment epithelium and ganglion cells — and, therefore, may save vision in people with a wide range of conditions.
May 23, 2023
The Retinal Cell and Gene Therapy Innovation Summit has emerged as one of the most essential events for researchers and companies developing treatments and cures for retinal degenerative diseases. In its eighth year, the Innovation Summit featured 30 presentations from retina experts from around the world with more than 300 people in attendance.
Feb 6, 2020
The Foundation Fighting Blindness is pleased to provide an audio recording and full transcripts of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on January 31, 2020.
The VISIONS Team is working hard to secure some of the world’s best researchers and clinicians in the field of retinal diseases to speak at VISIONS2018.
A regularly-updated table of inherited retinal diseases and dry AMD clinical trials